endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/2306-3513-2011-2-26-31endoserg-4007Research ArticleСтатьиArticlesВыбор объема хирургического вмешательства при медуллярном раке щитовидной железыChoice of surgery extension in medullary thyroid cancerRumyantsevP Opavelrum@gmail.comIlyinA A-RumyantsevaU V-20111506201152№2 (2011)2631Copyright © Rumyantsev P.O., Ilyin A.A., Rumyantseva U.V., 20112011Rumyantsev P.O., Ilyin A.A., Rumyantseva U.V.Rumyantsev P.O., Ilyin A.A., Rumyantseva U.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/4007

Медуллярный рак щитовидной железы (МРЩЖ) обладает высокой степенью клинической агрессивности и характе& ризуется склонностью к рецидивирующему течению, причем чаще развивается регионарный рецидив опухоли. Един& ственный радикальный метод лечения МРЩЖ–хирургический, поэтому изначальный выбор адекватного объема опе& рации способен улучшить показатели безрецидивной и общей выживаемости больных. В исследовании анализиру& ется опыт хирургического лечения 125 больных МРЩЖ, который в 25% случаев имел наследственно&генетическую природу (подтвержденную обнаружением герминальной RET/MT C мутации) и в 75% – спорадическую. Сопоставле& ние десятилетней безрецидивной выживаемости при различных объемах первичных операций на шее и регионарном лимфатическом коллекторе выявило, что выполнение тироидэктомии и центральной лимфодиссекции в качестве ми& нимального объема вмешательства достоверно улучшало показатели выживаемости по сравнению с таковыми при меньших по объему операциях.

Medullary thyroid cancer (MTC) has high level of clinical aggressiveness as well as high recurrence rate par& ticularly metastases in regional lymph nodes. Surgery is single curative treatment method thus only initial appropriate operation volume could improve disease&free and overall survival. In our study the experience of surgical treatment of 125 MTC patients is analyzing. In 25% of cases there were familial MTC (germline RET/MTC mutation verified) disease and in 75% – sporadic tumors. Comparison of ten&years disease&free sur& vival in two groups with various initial surgery extensions revealed that thyroidectomy associated with central neck dissection as a minimal operation volume has significantly improved long&term disease&free survival as against to lesser initial surgery extension.

медуллярный рак щитовидной железытиреоидэктомияцентральная лимфаденэктомияRETmedullary thyroid cancerthyroidectomycentral neck dissectionRETReferencesБржезовский В.Ж., Любаев В.Л. Диагностика и лечение медуллярного рака щитовидной железы. Практ. онкол. 2007; 8: 29–34.Бржезовский В.Ж., Любаев В.Л. Диагностика и лечение медуллярного рака щитовидной железы. Практ. онкол. 2007; 8: 29–34.Демидчик Ю.Е., Колобухов А.Э., Демидчик З.Э. и др. Результаты лечения больных медуллярным раком щитовидной железы. Онкол. журн. 2008; 3: 19–30.Демидчик Ю.Е., Колобухов А.Э., Демидчик З.Э. и др. Результаты лечения больных медуллярным раком щитовидной железы. Онкол. журн. 2008; 3: 19–30.Al-Rawi M., Wheeler M.H. Medullary thyroid carcinoma& update and present management controversies. Ann. R. Coll. Surg. Engl. 2006; 88: 433–438.Al-Rawi M., Wheeler M.H. Medullary thyroid carcinoma& update and present management controversies. Ann. R. Coll. Surg. Engl. 2006; 88: 433–438.Ball D.W. Management of medullary thyroid cancer. Minerva Endocrinol. 2011; 36: 87–98.Ball D.W. Management of medullary thyroid cancer. Minerva Endocrinol. 2011; 36: 87–98.De Groot J.W., Links T.P., Sluiter W.J. et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment&oriented surgery. Head & Neck 2007; 29: 857–863.De Groot J.W., Links T.P., Sluiter W.J. et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment&oriented surgery. Head & Neck 2007; 29: 857–863.Dionigi G., Bianchi V., Rovera F. et al. Medullary thyroid car& cinoma: surgical treatment advances. Expert. Rev. Anticancer Ther. 2007; 7: 877–885.Dionigi G., Bianchi V., Rovera F. et al. Medullary thyroid car& cinoma: surgical treatment advances. Expert. Rev. Anticancer Ther. 2007; 7: 877–885.Fialkowski E., DeBenedetti M., Moley J. Long&term outcome of reoperations for medullary thyroid carcinoma. World J. Surg. 2008; 32: 754–765.Fialkowski E., DeBenedetti M., Moley J. Long&term outcome of reoperations for medullary thyroid carcinoma. World J. Surg. 2008; 32: 754–765.Giraudet A.L., Vanel D., Leboulleux S. et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 2007; 92: 4185–4190.Giraudet A.L., Vanel D., Leboulleux S. et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 2007; 92: 4185–4190.Kloos R.T., Eng C., Evans D.B. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565–612.Kloos R.T., Eng C., Evans D.B. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565–612.Lodish M.B., Stratakis C.A. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert. Rev. Anticancer Ther. 2008; 8: 625–632.Lodish M.B., Stratakis C.A. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert. Rev. Anticancer Ther. 2008; 8: 625–632.Lundgren C.I., Delbridg L., Learoyd D. Robinson B. Surgical approach to medullary thyroid cancer. Arq. Bras. Endocrinol. Metab. 2007; 51: 818–824.Lundgren C.I., Delbridg L., Learoyd D. Robinson B. Surgical approach to medullary thyroid cancer. Arq. Bras. Endocrinol. Metab. 2007; 51: 818–824.Machens A., Hauptmann S. Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J. Surg. 2007; 31: 1960–1965.Machens A., Hauptmann S. Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J. Surg. 2007; 31: 1960–1965.Moley J.F., Fialkowski E.A. Evidence&based approach to the management of sporadic medullary thyroid carcinoma. World J. Surg. 2007; 31:946–956.Moley J.F., Fialkowski E.A. Evidence&based approach to the management of sporadic medullary thyroid carcinoma. World J. Surg. 2007; 31:946–956.Nosé V. Familial thyroid cancer: a review. Mod. Pathol. 2011; 24: S19–33.Nosé V. Familial thyroid cancer: a review. Mod. Pathol. 2011; 24: S19–33.Oskam I.M., Hoebers F., Balm A.J. et al. Neck management in medullary thyroid carcinoma. Eur. J. Surg. Oncol. 2008: 34: 71–76.Oskam I.M., Hoebers F., Balm A.J. et al. Neck management in medullary thyroid carcinoma. Eur. J. Surg. Oncol. 2008: 34: 71–76.Raval M.V., Sturgeon C., Bentrem D.J. et al. Influence of lymph node metastases on survival in pediatric medullary thy& roid cancer. J. Pediatr. Surg. 2010: 45: 1947–1954.Raval M.V., Sturgeon C., Bentrem D.J. et al. Influence of lymph node metastases on survival in pediatric medullary thy& roid cancer. J. Pediatr. Surg. 2010: 45: 1947–1954.Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107: 2134–2142.Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107: 2134–2142.Scollo C., Baudin E., Travagli J.P. et al. Rationale for central and bilateral lymph node dissection in sporadic and heredi& tary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2003: 88: 2070–2075.Scollo C., Baudin E., Travagli J.P. et al. Rationale for central and bilateral lymph node dissection in sporadic and heredi& tary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2003: 88: 2070–2075.Sippel R.S., Kunnimalaiyaan M., Chen H. Current management of medullary thyroid cancer. Oncologist 2008; 13; 539–547.Sippel R.S., Kunnimalaiyaan M., Chen H. Current management of medullary thyroid cancer. Oncologist 2008; 13; 539–547.Yen T.W., Shapiro S.E., Gagel R.F. et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003; 134: 890–901.Yen T.W., Shapiro S.E., Gagel R.F. et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003; 134: 890–901.

The authors declare that there are no conflicts of interest present.